206265-96-5 Usage
Uses
Used in Bioconjugation and Drug Synthesis:
t-boc-N-amido-PEG7-azide is used as a bioconjugation agent for the attachment of biomolecules, such as proteins, peptides, and other macromolecules, to PEG chains. The azide group facilitates the formation of stable triazole linkages through Click Chemistry, improving the stability and solubility of the resulting conjugates.
Used in Drug Delivery Systems:
In the pharmaceutical industry, t-boc-N-amido-PEG7-azide is used as a component in the development of drug delivery systems. The PEG spacer and reactive azide group allow for the creation of targeted drug conjugates with improved pharmacokinetics and reduced side effects.
Used in Polymer Science:
In polymer science, t-boc-N-amido-PEG7-azide is used as a building block for the synthesis of functional polymers with tailored properties. The azide group enables the formation of complex polymer architectures through Click Chemistry, while the Boc-protected amino group allows for further functionalization and modification of the polymer.
Used in Chemical Synthesis:
t-boc-N-amido-PEG7-azide is used as an intermediate in the synthesis of various chemical compounds, taking advantage of the reactivity of the azide group and the protecting properties of the Boc group. This molecule can be employed in the preparation of a wide range of products, from pharmaceuticals to specialty chemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 206265-96-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,6,2,6 and 5 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 206265-96:
(8*2)+(7*0)+(6*6)+(5*2)+(4*6)+(3*5)+(2*9)+(1*6)=125
125 % 10 = 5
So 206265-96-5 is a valid CAS Registry Number.
206265-96-5Relevant academic research and scientific papers
AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE
-
Page/Page column 115, (2016/06/01)
The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (I), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.e Antibody Drug Conjugates), pharmaceutical compositions comprising such cyclic peptides immunoconjugates, compositions comprising such cyclic peptides immunoconjugates with a therapeutic co-agent and methods of treatment using such cyclic peptides immunoconjugates: Formula (I).
